Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $775.03M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.26M
Average 1.02M
GLUE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Monte Rosa Therapeutics, Inc.NASDAQ: GLUE
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $4.21M fell 95.0% year over year, behind the -73.1% change in trailing-twelve-month revenue. Sequentially, it rose 51.4% from the prior quarter.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $103.14M (-16.6%) for the fiscal year ending Dec 2026, a slowdown from the +63.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.21M+51.4% QoQ
- Last fiscal yearDec 2025
- $123.67M+63.5% YoY
- LTMMar 2026
- $42.95M-73.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -95.0% | -44.3% | +50.7 pp |
| 1 year | +63.5% | -16.6% | -80.1 pp |
| 3-year CAGR | — | -0.8% | — |
| 5-year CAGR | +2.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 123.67M USD
- Year-over-year change
- +63.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 123.67M | +63.5% |
| FY2024 | 2024-12-31 | 75.62M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How GLUE compares with its peers on the latest reported figures
- GLUE's LTM Mar 2026 revenue of $42.95M is the 3rd highest of the 4 companies compared; the peer median is $89.4M.
- Its year-over-year change of -73.1% is the 3rd highest of 4, against a peer median of -12.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Mar 2026 | $89.4M | -79.1% | +26.0% | |
| LTM Mar 2026 | $42.95M | -73.1% | — | |
| LTM Mar 2026 | $34.86M | -12.4% | +5.0% | |
| Peer median (excluding GLUE) | $89.4M | -12.4% | +26.0% | |
Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 75.62M | 123.67M |
| Cost of Revenue | 0 | 0 | 6.22M | 8.12M | 8.36M |
| Gross Profit | 0 | 0 | (6.22M) | 67.5M | 115.32M |
| Gross Margin | — | — | — | 89.3% | 93.2% |
| Research & Development | 57.16M | 85.06M | 105.05M | 121.56M | 141.5M |
| Selling, General & Admin | 15.73M | 27.32M | 32.04M | 35.17M | 36.38M |
| Operating Expenses | 72.88M | 112.38M | 137.09M | 148.61M | 169.52M |
| Depreciation & Amortization | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| EBITDA | (71.83M) | (100.99M) | (128.79M) | (62.01M) | (31.37M) |
| EBITDA Margin | — | — | — | -82.0% | -25.4% |
| Operating Income | (72.88M) | (112.38M) | (143.31M) | (81.11M) | (54.21M) |
| Operating Margin | — | — | — | -107.3% | -43.8% |
| Interest Income | 46K | 3.76M | 9.33M | 10.57M | 12.94M |
| Interest Expense | 0 | 3.76M | 0 | 0 | 0 |
| Other Income / Expenses | (1.08M) | 3.88M | 8.3M | 10.98M | 14.49M |
| Income Before Tax | (73.96M) | (108.5M) | (135.01M) | (70.13M) | (39.72M) |
| Pre-Tax Margin | — | — | — | -92.7% | -32.1% |
| Income Tax Expense | 0 | 0 | 338K | 2.57M | (1.1M) |
| Net Income | (73.96M) | (108.5M) | (135.35M) | (72.7M) | (38.63M) |
| Net Margin | — | — | — | -96.1% | -31.2% |
| EPS (Basic) | (1.59) | (2.30) | (2.63) | (0.98) | (0.46) |
| EPS (Diluted) | (1.59) | (2.30) | (2.63) | (0.98) | (0.46) |
| Weighted Avg Shares | 46.54M | 47.23M | 51.4M | 73.91M | 83.07M |
| Weighted Avg Shares (Diluted) | 46.54M | 47.23M | 51.4M | 73.91M | 83.07M |
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
Intrinsic Alpha fair value
Locked
Current Price
$9.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.